BI vs CORONA: Stock Comparison
CORONA REMEDIES is the larger company by market capitalisation. BI shows lower leverage, while CORONA REMEDIES shows a higher ROE, a higher dividend yield and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BI leads 4; CORONA leads 5 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BI | CORONA |
|---|---|---|
| Live Price | ₹91.66 | ₹2,441.1 |
| Day Change | -9.59% | 2.58% |
| Volume | 10.06 L | 1.45 L |
| 52-Week High | ₹111.51 | ₹2,458 |
| 52-Week Low | ₹51.62 | ₹1,336.6 |
| Distance from 52W High | -17.8% | -0.69% |
Valuation
| Metric | BI | CORONA |
|---|---|---|
| Market Cap | ₹171 Cr | ₹15,290 Cr |
| P/E Ratio | — | 73.86x |
| P/B Ratio | — | 18.99x |
| EPS | ₹5.39 | ₹9.86 |
| Book Value | ₹31.49 | ₹122.12 |
| Dividend Yield | 0% | 0.4% |
Growth
| Metric | BI | CORONA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 20.36% | 4.44% |
| Qtr Profit Growth | 90.7% | 0.33% |
Profitability & Leverage
| Metric | BI | CORONA |
|---|---|---|
| ROE | 0.24% | 24.78% |
| ROCE | 0.5% | 21.44% |
| Net Margin | -2.36% | 13.19% |
| Operating Margin | 31.53% | 17.61% |
| Debt to Equity | 0.03x | 0.19x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BI | CORONA |
|---|---|---|
| Promoter Holding | 30.01% | 69% |
| FII Holding | 0.04% | 4.21%▲ 0.58 pp |
| DII Holding | 0% | 16.45%▲ 3.55 pp |
| Public Holding | 69.94% | 10.34%▼ 4.14 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BI and CORONA REMEDIES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.